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Abstract
Background: CKD is common in heart failure (HF) and associated with morbidity and mortality, yet life-prolonging
medications such as renin-angiotensin-aldosterone inhibitors (RAASi) are underused due to risk of hyperkalaemia.
Sodium zirconium cyclosilicate (SZC) is a potassium-binding medication that has been shown to reduce incidence of
hyperkalaemia in CKD, non-CKD, and HF populations, which we propose will support maximisation of RAASi therapy.
Methods: We propose a 1:1 randomised, double-blind, placebo-controlled trial in which participants will receive either
SZC or placebo. We will up-titrate participants’ RAASi therapy while monitoring their serum potassium levels and
adjusting their SZC dose if necessary. Participants with CKD and HF will be recruited from CKD and HF clinics at St
George’s Hospital. The total study period will be 18months; 130 participants will be enrolled for approximately two
months each following screening. Our primary outcome will be the proportion of participants who achieve maximum
RAASi dose while maintaining normokalaemia. Secondary outcomes include participants reaching maximum RAASi
dose without severe hyperkalaemia; time from randomisation to hyperkalaemia; time from randomisation to severe
hyperkalaemia; number of RAASi dose escalations per participant; final doses of RAASi therapy; changes in quality of life
score, eGFR, ACR, serum sodium, troponin T; number and duration of hospital admissions; and within-participant
change in serum potassium compared to baseline.
Discussion: This trial will be the first to examine the use of SZC for the maximisation of RAASi dosing in patients with
advanced CKD and HF. We will assess the impact of achieving target RAASi dosing on hospital admission rates and
duration of stay, with the hope that optimum RAASi treatment will translate into reduced morbidity and improved
QoL. If clinical benefit is demonstrated, we hope that the joint multidisciplinary CKD-HF approach will be expanded.
Trial registration: EudraCT number 2020–002946-18. Registered on 08 June 2020. Online record pending.
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Background
Chronic kidney disease (CKD) is a common comorbidity
in individuals with heart failure (HF), with a prevalence
of 32% according to a 2013 meta-analysis of over one
million individuals [1]. Patients with combined CKD-HF
are at 2.3 times greater risk of all-cause mortality than
those with HF alone [1]. Potentially life-saving medications
for systolic HF are underused in combined CKD-HF
due to risk of hyperkalaemia [2]. These medications
include renin-angiotensin-aldosterone system inhibitors
(RAASi): angiotensin converting enzyme inhibitors
(ACEi), angiotensin receptor blockers (ARB), and min-
eralocorticoid receptor antagonists (MRA) [3, 4].
While numerous national and international guidelines
recommend RAASi treatment in patients with combined
CKF-HF [5–8], the risk of hyperkalaemia in CKD stage
4/5 patients is high and potentially fatal [9]. There is
therefore reluctance amongst general practitioners,
general physicians, and cardiologists managing these pa-
tients to prescribe medications that may increase serum
potassium levels [10].
In a study of 1056 acute heart failure admissions in
851 patients at St George’s Hospital, London, patients
with CKD stage 4/5 and systolic HF were less likely to
receive ACEi or ARB compared to non-CKD patients
(36% vs 84%, p < 0.001) and less likely to receive MRA
(17% vs 57%, p < 0.001) [11]. These findings have led to
the establishment of a joint kidney failure-heart failure
service at St George’s Hospital, funded by three local
clinical commissioning groups, to improve care for these
patients. Audit of all new referrals to the kidney failure-
heart failure clinic between March and September 2017
showed that only 3% of all patients with left ventricular
systolic dysfunction were on maximum-dose ACEi/ARB,
and only 2% were on maximum-dose MRA [12].
Recent studies have shown that sodium zirconium
cyclosilicate (SZC) can lower serum potassium concentra-
tions in non-CKD, CKD, and HF populations [13–16].
SZC is a zirconium silicate compound that acts as a select-
ive potassium ion trap and is not absorbed from the
gastrointestinal tract [17]. In a phase three randomised
controlled trial of 258 patients with hyperkalaemia, SZC
lowered serum potassium from 5.6 to 4.5mmol/L in 48 h
and maintained serum potassium of < 5.1mmol/L in 90%
of patients (compared with 48% of patients on placebo,
p < 0.001) [15].
Most studies of potassium binders have been short and
none have investigated exclusively the high-risk group of
patients with advanced CKD-HF, particularly with an aim
to maximise RAASi therapy. Furthermore, this study will
augment the currently-limited safety and efficacy data on
RAASi maximisation in advanced CKD patients.
The St George’s experience suggests the need for a
trial and subsequent clinical implementation of RAASi
maximisation in patients with combined CKD-HF. There
are significant numbers of patients in our own clinics
who may benefit from recruitment into a trial of RAASi
maximisation. We therefore propose a 1:1 randomised,
double-blind, placebo-controlled trial to investigate the
potential benefits of SZC in patients with CKD and HF
on maximisation of RAASi therapy.
Methods & design
Study setting
Participants will be recruited from the joint kidney
failure-heart failure clinic and from other heart failure
clinics at St George’s Hospital. Patients discharged from
the heart failure wards and inpatients admitted with
acute heart failure and referred to the heart failure team
will also be approached to take part. The study is being
conducted in conjunction with St George’s, University of
London and has been approved by the Cambridge NHS
Research Ethics Committee [281626], NIHR portfolio




For inclusion in the study patients must fulfil all of the
following criteria:
(1) Age > 18 years
(2) Heart failure, clinical or echo confirmed (HFrEF i.e.
ejection fraction < 40%); patients with atrial fibrillation
will be included provided the EF can be determined
(3) New York Heart Association class II to IV
(4) Most recent serum potassium 5.0–5.5 mmol/L
(5) Adequate blood pressure (BP) (> 90 mmHg systolic
and without postural hypotension; drop of systolic
blood pressure (SBP) > 20 mmHg or feeling dizzy
with change in posture; exclude patients with
symptomatic hypotension due to high doses of
ACEi/ARB or MRA unless the clinical condition
has improved)
(6) Formal diagnosis of CKD (i.e. two measurements of
eGFR < 60mL/min/1.73 m2 taken ≥3 months apart)
with stable eGFR < 60 mL/min/1.73m2. eGFR to be
calculated according to the CKD-Epi formula [18],
measured at a single time-point.
(7) None or submaximal dose of ACEi/ARB and/or
MRA.
Exclusion criteria
Patients should not enter the study if any of the follow-
ing exclusion criteria are fulfilled:
Pregnancy: individuals of childbearing potential must
have a negative pregnancy test within 7 days prior to
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treatment initiation and agree to use highly-effective
contraception for the trial period
(1) Active malignancy or infection
(2) BMI > 35 kg/m2
(3) Poorly controlled blood sugar (HbA1c > 70 mmol/
mmol)
(4) Recent Acute Coronary Syndrome (ACS) i.e. within
three months
(5) Ongoing potassium therapy
(6) Prolonged QT > 550 ms, congenital QT syndrome
and history of prolonged QT requiring drug
discontinuation
(7) Currently breastfeeding
(8) Allergies to excipients of investigational medicinal
product (IMP) or placebo
(9) Inability to consent
Recruitment
Participants will be identified by the research team from
the clinics mentioned above by consulting clinic lists
and patients’ blood test results. Potential participants
nearing discharged from hospital will be referred to the
research team for participation, provided they are stable
and would benefit from RAASi maximisation. Eligibility
for the study in all cases will be confirmed by the Princi-
pal Investigator (PI) or another study doctor. All patients
who fit the eligibility criteria for the study will be
approached. At this initial contact, potential participants
will be informed of the nature and objectives of the
study and any potential risks of participation. If partici-
pants agree to take part, they will be invited for screening.
At screening, all participants will have their last three
months’ blood tests results for potassium and creatinine
reviewed. An electrocardiogram (ECG) will be per-
formed to record participants’ QT interval and further
blood samples will be taken for analysis (see Study Time-
line below). These tests may be done as part of standard
care if clinically necessary. Participants of childbearing
potential will be required to take a urine pregnancy test.
Eligible participants will be asked to complete an E5-QD
quality-of-life (QoL) questionnaire and will receive edu-
cational material on low sodium / low potassium diets.
Again, the PI or study doctor will confirm eligibility in
all cases.
Full informed consent will be obtained prior to a par-
ticipant undergoing any study activities. All potential
participants will undergo assessment of capacity, with
the opportunity for potential participants to ask ques-
tions and have a period of at least 24 h to consider if
they would like to take part. The study team will assess
if the participant is able to:
(1) Understand the purpose and nature of the research;
(2) Understand what the research involves, its benefits,
risks and burdens;
(3) Understand the alternatives to taking part;
(4) Retain the information long enough to make an
effective decision;
(5) Be able to make a free choice;
(6) Be capable of making this particular decision at the
time it needs to be made (though their capacity
may fluctuate, and they may be capable of making
some decisions but not others depending on their
complexity).
If the above criteria are met, written consent may be
taken by the PI or study doctor. All participants may
refuse or discontinue involvement at any time without
giving a reason for doing so.
Randomisation
Participants will be randomised 1:1 to either the placebo
or active (SZC) arm of the trial. Randomisation is strati-
fied by patients’ baseline RAASi dose at the start of the
trial (individuals on < 50% standard dose vs those on
≥50% standard dose) to ensure equal proportions of
RAASi therapies in each group.
We will use the REDCap Randomisation Module
(https://wiki.uiowa.edu/display/REDCapDocs/REDCap+
Randomization+Module). This module can be turned on
by selecting the “Enable the randomization module”
checkbox during project creation or after. This would
preserve the randomisation procedure independent of
the study statistician.
Randomisation will be implemented by the research
pharmacy at St George’s. Randomisation codes will be
generated by the study statistician on an external spread-
sheet. The research pharmacy will be informed by the
study team as soon the patient is consented, and will use
the randomisation list to assign the participant to their
allocated arm. In the case of an adverse event or patient
safety issue, emergency unblinding will be performed by
the on-call research pharmacist.
Confidentiality
The study will be carried out in accordance with Good
Clinical Practice guidance and UK data regulation legis-
lation. All participants will be given an anonymous study
ID, which will be used for all data and samples collected.
Participants’ personal details will be stored in paper files
in a locked office, access to which will be restricted to
necessary personnel. Study team members looking at
data collected or test results will not be able to see par-
ticipants’ personal details. All personal information will
be destroyed one year following the end of the study.
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Risk in the context of the COVID-19 pandemic
In the context of the COVID-19 pandemic, one potential
safety concern is that required two-weekly study ap-
pointments may increase the risk of participants being
exposed to SARS-CoV-2. A COVID-19 risk assessment
has been performed, all study personnel will be
instructed and trained in infection control measures
and, where possible, social distancing practises will be
observed.
Study timeline
The study activity schedule is outlined in Table 1 and
represented schematically in Fig. 1. Baseline data will be
recorded on electronic case report forms (eCRFs) and
will include demographic information (age, gender, ethni-
city), clinical co-morbidities (e.g. diabetes, hypertension,
ischaemic heart disease), cardiovascular risk factors (e.g.
hypercholesterolaemia, BMI, smoking, family history of
cardiac disease), blood test results (e.g. serum haemoglo-
bin, ferritin, urea, creatinine, sodium, potassium, calcium,
phosphate, B-type natriuretic protein [BNP], troponin,
parathyroid hormone [PTH]), ECG, and echocardiogram
results. In addition, we will record pulse rate, blood pres-
sure (average of three readings), weight, presence of
oedema, presence of chest crepitations, signs of raised
jugular venous pressure, Rockwood clinical frailty score,
and E5-QD QoL questionnaire score. The end-of-trial visit
will record the same data.
At initial visit, participants will be initiated on placebo
or SZC at initiation dose (i.e. 10 g three times daily). If
participants are already taking RAASi medication, they
will continue their current medication. If not, the study
Table 1 Study activity schedule and procedures
Screening C1 C2 C3 C4 C5 C6 C7 or final visit
Week 0 0 Every 2 weeks ±2 days




Targeted physical exam (based on symptoms) X X X X X X X X
Vital signs X X X X X X X X
Past medical history






Baseline blood tests X
iSTAT sK X X X X X X X X
Lab serum K X X X X X X X X
Laboratory safety assessment X X X X X X X
Monitoring
AE/SAE assessment Ongoing
Drug dosing and monitoring
LOKELMA/Placebo X X X X X X X
RAASi X X X X X X X
Diuretics use X X X X X X X X
Efficacy evaluations/Other assessments and assays
Quality of Life assessment X X
Hospitalization assessment X X X X X X X
HF symptom assessment X X X X X X X
Table 1—Study schedule of procedures. C6 (i.e. 7 visits total) will occur only in participants not prescribed RAASi at study entry. Baseline blood tests: serum
haemoglobin, ferritin, urea, creatinine, sodium, potassium, BNP, troponin, calcium, phosphate, PTH. Laboratory safety assessment: serum sodium,
potassium, creatinine
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doctor will start them on appropriate RAASi therapy per
local guidance. Participants will be reviewed at 48 h
where they will have serum potassium concentration
measured and enter the maintenance phase. If serum
potassium is 3.5–5.0 mmol/L, participants will begin
standard maintenance-dose SZC (i.e. 5 g once daily).
For other serum potassium concentrations, and for
the remainder of the maintenance phase, dosing will
be titrated as outlined in Table 2. If participants
experience other adverse effects from RAASi therapy
(e.g. symptomatic hypotension, < 90 mmHg recorded
systolic blood pressure, postural hypotension), their
RAASi dose will be down-titrated if clinically
indicated.
After screening, recruitment, and randomisation, visits
will take place every two weeks (± two days) until the end
of the study. The number of visits will depend on partici-
pants’ baseline dose of ACEi / ARB / MRA. Patients with
Fig. 1 Study flow chart. Flow chart demonstrating design of the study. ACEi = ACE inhibitor, ARB = angiotensin receptor blocker, eGFR =
estimated glomerular filtration rate, HFrEF = heart failure with reduced ejection fraction, MRA =mineralocorticoid receptor antagonist, OD = once
daily, QOL = quality of life, SBP = systolic blood pressure, TDS = three times daily
Table 2 IMP dosage protocol
SZC dose at start of visit Serum potassium at visit Dose change at end of visit
On 10 g daily 5.0–6.0 mmol/L Continue 10 g daily
3.5–5.0 mmol/L Change to 5 g daily
< 3.5 mmol/L Stop
> 6.0 mmol/L Stop and initiate rescue
On 5 g daily > 5.0 mmol/L Change to 10 g daily
3.5–5.0 mmol/L Continue 5 g daily
< 3.5 mmol/L Stop
On 0 g daily (i.e. temporary stop) ≤ 5.0 mmol/L Continue with no IMP
> 5.0 mmol/L Initiate 5 g daily
Table 2—Dosage protocol for study visits based on serum potassium measurements. IMP may be restarted two weeks after discontinuation due to hypokalaemia
depending on serum potassium result
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no prescribed RAASi at baseline will have seven visits, and
others will have six visits.
Following the final study visit, there will be no further
follow up visits related to the trial.
Sample collection and analysis
Serum samples will be obtained by venepuncture by one
of the research team. Samples for potassium, sodium,
calcium, phosphate, urea, creatinine, ferritin, troponin T
and BNP testing will be collected into 5 mL SST tubes.
Samples for haemoglobin and PTH testing will be col-
lected into 4mL EDTA tubes. All analysis will be carried
out at the NHS South West London Pathology labora-
tory at St George’s Hospital. With participant consent,
serum samples will be saved and stored in a − 80 °C
freezer in the Cardiovascular Research Institute at St
George’s for the duration of the study.
IMP and placebo information
The unlabelled study drug (SZC, brand name Lokelma®)
or placebo will be provided by AstraZeneca PLC (Cam-
bridge, UK) and delivered to St George’s research phar-
macy in bulk. Lokelma® is licensed for use in the UK and
European Union for the treatment of hyperkalaemia.
The study drug will be labelled upon receipt by an inde-
pendent company (RenaClinical, Horley, UK) and
prepared in accordance with Good Manufacturing Prac-
tice and local regulatory guidance.
The study drug will be supplied as a powder for oral
suspension in 5 g or 10 g sachets. The entire contents of
the sachet should be emptied into a drinking glass con-
taining approximately 45 mL of water and stirred well.
The powder does not dissolve, and the tasteless liquid
should be consumed while still cloudy. The study drug
does not require any special storage conditions, can be
taken with or without food, and can be taken with many
other medications.
Outcomes
The main clinical outcome measure will be serum potas-
sium concentration, which will be measured every two
weeks, and the dose of RAASi at the end of the study.
The statistical outcome measure will be achieving target
level of RAASi without hyperkalaemia (i.e. serum potas-
sium ≥5.6 mmol/L). Target RAASi doses are defined as
maximum dosing as in Table 3. Outcomes are also dis-
played in Table 4.
Primary outcomes
Participants will be classified as either responders or
non-responders, where a responder is a participant who
achieves their target RAASi dose with no post-
randomisation serum potassium measurements ≥5.6
Table 3 Dose classification of RAASi therapy
Minimum dose Half maximum dose Maximum dose
ACEi
Ramipril 2.5 mg OD 5mg OD 10mg OD
Perindopril arginine 2.5 mg OD 5mg OD 10mg OD
Enalapril 2.5 mg OD 5mg OD 10 / 20 / 40 mg OD
Lisinopril 2.5 mg OD 5 / 10 mg OD 20 / 40 mg OD
Perindopril erbumine 2 mg OD 4mg OD 8 / 16mg OD
ARB
Losartan 25 mg OD 50mg OD 100mg OD
Candesartan 4 mg OD 8 / 16 mg OD 32mg OD
Irbesartan 75 mg OD 150mg OD 300mg OD
Telmisartan 20 mg OD 40mg OD 80mg OD
Olmesartan 10 mg OD 20mg OD 40mg OD
Valsartan 40 mg BD 80mg BD 160mg BD
MRA
Spironolactone 12.5 mg OD 25mg OD 50mg OD
Eplerenone 12.5 mg OD 25mg OD 50mg OD
ARNI
Valsartan + sacubitril 24 / 26 mg BD 49 / 51 mg BD 97 / 103 mg BD
Table 3—ARNI = angiotensin receptor-neprilysin inhibitor, BD = twice daily, OD = once daily. For analysis and dose titration, participants’ RAASi doses will be
classified as low / medium / maximum based on the values in this table. Note—this is not a dose conversion table
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mmol/L. Participants who discontinue the study before
completion will be deemed as missing.
Secondary outcomes
(1) Responder / non-responder classification, where a
responder is defined as a patient who achieved
maximum dose of MRA and ACEi/ARB with serum
potassium ≤5.6 mmol/L;
(2) Responder / non-responder classification, where a
responder is defined as a patient who achieved
maximum dose of MRA and or ACEi/ARB and
serum potassium ≤6.0 mmol/L;
(3) Time from randomisation to hyperkalaemia (serum
potassium ≥5.6 mmol/L);
(4) Time from randomisation to severe hyperkalaemia
(serum potassium > 6.0 mmol/L);
(5) Number of RAASi dose escalations per patient;
(6) Final doses of ACEi/ARB, MRA;
(7) Change in QoL score, eGFR, ACR, BNP, serum
sodium, troponin T at event / end as compared to
baseline;
(8) Number of hospital admissions per patient, as well
as duration of hospital admissions;
(9) Within-patient change in serum potassium as
compared to baseline;
Statistical analysis and sample size
Summary of baseline data and flow of patients
We will perform an intention-to-treat analysis. The pri-
mary outcome (i.e. responder / non-responder status)
will be analysed via χ2 test with α = 0.05. The proportion
of responders in each arm, the difference thereof, and
the 95% confidence interval for the difference in propor-
tions will be reported.
Additional analyses may be performed to explore the
consistency of the effect across subgroups, for instance
defined by the degree of MRA and/or ACEi/ARB treat-
ment at baseline. Provided the modelling assumptions
are satisfied (e.g. sufficient numbers of responders /
non-responders in each arm), these will be done by lo-
gistic regression.
If there is loss to follow-up, sensitivity analysis will be
conducted. Given the binary nature of the primary out-
come, extreme scenarios such as the worst case in the
intervention group (all losses to follow-up classified as
non-responders) and the best case in the control group
(all losses to follow-up are responders) will be
considered.
Secondary outcome analysis
Descriptive summaries of the distribution of the second-
ary endpoints will be presented. More formal statistical
analysis and modelling may also be performed: for re-
sponder/non-responder outcome (e.g. secondary out-
comes 1 and 2), analysis may be done in the same
manner as for the primary outcome. For time-to-event
endpoints (e.g. secondary outcomes 3 and 4), survival
techniques such as Kaplan-Meier estimates may be
employed. The exact choice of analyses will be data-driven,
so these analyses are to be regarded as explanatory.
Sample size estimation
Clinical evidence suggests that the proportion of patients
reaching the target dose of RAASi in the control arm
would be around 50% as a conservative estimation based
on our experience. The study is powered to detect an ef-
fect size of the intervention of around 30%.
Group sample sizes of 52 will achieve approximately
90% power to detect a difference between the group pro-
portions of 0.3 using a two-sided Z-test with pooled
Table 4 Primary and secondary study outcomes
Objectives Outcome measures Timepoints of evaluation
Primary Objective:
To compare SZC vs
placebo with respect to:
Enabling participants to achieve target RAASi dose
while keeping serum potassium < 5.6 mmol/L.
Blood test for potassium and RAASi dose
Secondary Objectives:
To compare SZC vs
placebo with respect to:
Achieving maximum dose of MRA and ACEi/ARB with
serum potassium < 5.6 mmol/L
Achieving maximum dose of MRA and ACEi/ARB with
serum potasssium < 6.0 mmol/L
Time since randomisation to first occurrence of
hyperkalaemia (serum potassium ≥5.6 mmol/L)
Time since randomisation to severe hyperkalaemia
(serum potassium ≥6.0 mmol/L)
Number of ACEi/ARB, MRA dose changes
Number and durationof hospital admissions during the
study
Change in serum potassium at respective visits vs
baseline
Blood test for potassium and RAASi dose ever two weeks. Other
parameters checked at baseline and end of study.
Tertiary Objectives: None
Table 4—Primary and secondary study outcomes
Murphy et al. BMC Nephrology          (2021) 22:254 Page 7 of 9
variance and a two-sided χ2 test. The proportion of re-
sponders in the placebo arm is assumed to be 0.5 with
the corresponding proportion in the active arm 0.8
under the alternative hypothesis. The significance level
(α) of the test is 0.05. This results in a total of 104 pa-
tients required and, accounting for 20% loss to follow-
up, we will recruit 130 patients to be randomised to each
group.
Interim analysis and criteria for trial termination
An interim analysis reviewing feasibility and tolerability
will be performed once 10% of patients have completed
the study. We envisage a further two interim analyses,
upon collection of 50 and 75% of events. No early con-
clusions will be drawn until data collection is completed
and the data is locked.
Procedure(s) to account for missing or spurious data
If data exhibit missing or spurious values, the circum-
stances of their collection, recording, and analysis will be
investigated. Appropriate statistical analysis would be
carried out depending on the type of data missing (i.e.
independent or dependent variables).
Data management and security
Data will be collected into eCRFs and accessible to
members of the study team by a unique username-
password combination. Participants’ clinical data is
stored securely by St George’s University Hospitals NHS
Foundation Trust. Access will be granted to authorised
representatives of the Sponsor, host institution, and
regulatory authorities to permit trial-related monitoring,
audit, and inspection in line with participant consent.
Data management will comply with EU General Data
Protection Regulation (2018) and the UK Data Protec-
tion Act (2018).
Dissemination policy
The Chief Investigator will liaise with all investigators to
compile data and submit a manuscript for peer review
with a view to publication in a reputable scientific jour-
nal within 180 days of study completion (i.e. the “Main
Publication”). Following the Main Publication, other in-
vestigators may prepare further publications. Results
from the study will also be communicated to trial partic-
ipants and local and national patients’ associations.
Discussion
This trial will be the first to look at the use of SZC for
the maximisation of RAASi dosing in CKD patients. Our
hypothesis is that SZC therapy will reduce the incidence
of treatment-limiting hyperkalaemia in CKD-HF pa-
tients, allowing higher doses of RAASi therapy and
therefore better clinical outcomes. Achievement of the
participant’s target RAASi dose is the primary endpoint,
and secondary endpoints include measures to assess
safety in terms of hyperkalaemia, cardiovascular risk in
terms of troponin T levels [19, 20], and efficacy in terms
of time-to-target dose. We will also assess the impact of
achieving target RAASi dosing on hospital admission
rates and duration of stay, with the hope that optimum
RAASi treatment will translate into reduced morbidity
and improved QoL.
The strengths of the study include its randomised,
double-blind design, and the favourable safety profile of
the trial drug. We intend that the design will provide
high-quality evidence that, if our hypothesis is sup-
ported, will help guide changes in clinical practise. As
SZC is approved for the treatment of hyperkalaemia in
the UK and has a favourable safety profile, our study has
the benefit of being low-risk to participants.
The side-effect profile of SZC is minimal and hence
we hope that adherence to the study protocol will be sat-
isfactory. Our statistical predictions have nonetheless
accounted for a 20% dropout rate owing to participants’
decisions, movements out of the area, death, progression
to renal transplant, or other causes. Our study design fo-
cusses on a single recruitment centre.
The novel value of this study centres around (I) its ex-
aminations of SZC to limit hyperkalaemia and allow
RAASi maximisation in the under-studied combined
CKD-HF patient group, and (ii) its expansion of the cur-
rently limited safety data on the use of RAASi therapy in
advanced CKD patients. The joint CKD-HF clinic ap-
proach is an emerging practise, and, if clinical benefit is
proven, we would hope to investigate future studies with
wider scope for more extensive population validity.
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